MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
May 31, 2022
Canopy Growth (CGC, $4.88) disappoints on Q1 results

Canopy Growth (CGC, $4.88) disappoints on Q1 results

Canopy Growth announced its quarterly earnings results that missed analysts’ expectations.

The cannabis company reported ($1.46) loss per share for the quarter, missing the consensus estimate of ($0.24), Briefing.com reports. Revenue of $126.10 million, down 24.7% from the year-ago quarter, also was below  analyst estimates of $130.34 million.

Cash was at $1.4 billion as of the quarter’s end, versus $1.5 billion in long term debt. The company had a net cash position of $4 billion in 2018 but has since burned through  a lot of it.

Related Ticker: CGC

CGC's Stochastic Oscillator sits in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CGC moved out of overbought territory on December 18, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on January 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGC as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CGC turned negative on December 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

CGC moved below its 50-day moving average on January 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CGC crossed bearishly below the 50-day moving average on January 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CGC entered a downward trend on January 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.842) is normal, around the industry mean (29.670). P/E Ratio (0.000) is within average values for comparable stocks, (76.301). CGC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.044). CGC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (1.070) is also within normal values, averaging (111.454).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.62B. The market cap for tickers in the group ranges from 2.12K to 65.62B. MKKGY holds the highest valuation in this group at 65.62B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 1%. For the same Industry, the average monthly price growth was 9%, and the average quarterly price growth was 15%. SHPH experienced the highest price growth at 53%, while GENPF experienced the biggest fall at -53%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 18% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 63
Price Growth Rating: 56
SMR Rating: 80
Profit Risk Rating: 89
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
CGC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CGC showed earnings on November 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a producer of medical marijuana

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Agricultural Commodities Or Milling
Address
1 Hershey Drive
Phone
+1 855 558-9333
Employees
1621
Web
https://www.canopygrowth.com
Interact to see
Advertisement
Tickeron, a leader in AI-powered trading solutions, announces its AI Trading Agent’s impressive 36% annualized return on a portfolio of eight tickers: META, TSM, WMT, NVDA, AVGO, AAPL, XAR, and ITA.
Cintas Corporation (NASDAQ: CTAS), a leading provider of specialized business services, has delivered a remarkable 19.88% stock price increase in 2025, captivating investors and analysts alike.
#artificial_intelligence#trading
Introduction: A Colossal Leap for TSM Taiwan Semiconductor Manufacturing Company (TSM), the world’s largest contract chipmaker, has experienced a remarkable 30.44% stock price surge in 2025, with an average daily trading volume of 15 million shares.
#artificial_intelligence
The satellite telecommunications sector witnessed one of the most remarkable stock performances in 2025 as AST SpaceMobile, Inc. (ASTS) delivered an extraordinary 211% gain from its April 7 low of $18.22 to its July 21 closing price of $56.67.
#artificial_intelligence
Joby Aviation Inc. (JOBY) has delivered one of the most spectacular performances in the aviation sector during 2025, with its stock price surging approximately 240% from its April low of $4.96 to the July 21 closing price of $16.84.
#artificial_intelligence
A Remarkable Rise for VAPE CEA Industries Inc. (NASDAQ: VAPE), a company specializing in controlled environment agriculture solutions, has captured the attention of investors with its extraordinary stock performance.
#artificial_intelligence
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a clinical-stage biopharmaceutical company focused on innovative cancer therapies, has captured the attention of investors with a staggering 251.95% stock price surge over the past five trading days as of July 22, 2025, accompanied by an average daily trading volume of 1 million shares.
#artificial_intelligence
The stock market in 2025 continues to be a dynamic arena, with technology and innovation-driven companies leading the charge. Among the most closely watched are Alphabet Inc. (GOOG), International Business Machines Corporation (IBM), and Tesla, Inc. (TSLA).
Tesla’s Meteoric Rise in 2025 Tesla, Inc. (NASDAQ: TSLA) has captivated investors with a colossal 37.33% year-to-date (YTD) stock price surge in 2025, accompanied by an average daily trading volume of 98 million shares.
Wang & Lee Group, Inc. (NASDAQ: WLGS), a Hong Kong-based construction contractor specializing in electrical, mechanical, and fire safety systems, has captured significant market attention with an extraordinary 220.68% stock price surge over the past five trading days as of July 24, 2025.
#artificial_intelligence
Union Pacific Corporation (NYSE: UNP), the largest publicly traded railroad company in North America, is poised to release its second-quarter 2025 earnings on July 24, 2025, before the market opens.
#artificial_intelligence
In the fast-evolving landscape of financial markets, artificial intelligence (AI) has redefined the boundaries of trading efficiency and profitability. As of July 24, 2025, AI trading agents have emerged as powerful tools, leveraging advanced Financial Learning Models (FLMs) to deliver unprecedented returns.
#artificial_intelligence
This year, the stock gained +41.63% with an average daily volume of 3 million shares traded.The stock tracked a drawdown of -22.95% for this period. NDAQ showed earnings on April 24, 2025.
#artificial_intelligence
In July 2025, Ethereum (ETH.X) has solidified its position as a powerhouse in the cryptocurrency market, achieving a staggering 48.73% price surge with an average daily trading volume of 569,180 shares.
Tesla, Inc. (NASDAQ: TSLA) has experienced a volatile yet captivating journey in 2025, marked by a staggering 90% stock price surge in June, followed by a sharp 8% decline in a single trading session.
The financial markets have undergone a transformative shift with the integration of artificial intelligence (AI), particularly in trading high-profile stocks like Amazon (AMZN), Taiwan Semiconductor Manufacturing Company (TSM), Walmart (WMT), Google (GOOG), and Meta Platforms (META).
#artificial_intelligence
In the dynamic world of financial markets, artificial intelligence (AI) continues to redefine trading strategies, offering precision and adaptability that surpass traditional methods.
#artificial_intelligence
Cineverse Corp. (CNVS), a company operating in the communication services sector with a focus on digital entertainment and streaming platforms, experienced a significant downturn in its stock price over the past five trading days as of July 25, 2025.
#artificial_intelligence
Artificial Intelligence (AI) is no longer a futuristic concept in finance—it’s the present. Nowhere is this more evident than in the world of algorithmic trading, where intelligent bots analyze, adapt, and execute trades at speeds and accuracy levels humans simply can’t match.
#artificial_intelligence